Sahinovic, Ayshe http://orcid.org/0000-0003-0717-2342
Irwin, Christopher
Doohan, Peter T.
Kevin, Richard C.
Cox, Amanda J.
Lau, Namson S.
Desbrow, Ben
Johnson, Nathan A.
Sabag, Angelo
Hislop, Matthew
Haber, Paul S.
McGregor, Iain S.
McCartney, Danielle
Funding for this research was provided by:
The Lambert Initiative for Cannabinoid Therapeutics
Article History
Received: 2 November 2021
Accepted: 1 February 2022
First Online: 2 March 2022
Declarations
:
: This investigation was approved by the Sydney Local Health District’s Human Research Ethics Committee (2020/ETH00226), registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12620000941965) and conducted in accordance with Good Clinical Practice guidelines, the Declaration of Helsinki (1983) and local regulations. Participants provided written informed consent prior to participation in the trial.
: Not applicable.
: P.T.D., R.C.K., I.S.M. and D.M receive salary support from the Lambert Initiative for Cannabinoid Therapeutics. I.S.M. also acts as a consultant to Kinoxis Therapeutics and an advisor to Psylo and Emyria and is an inventor on several patents relating to novel cannabinoid therapeutics, none of which relate to sports physiology or medicine. A.S., C.I., A.J.C., N.L., B.D., N.A.J., A.S., M.H. and P.H. have no conflicts of interest to disclose.